Hua Yan

1.3k total citations
22 papers, 251 citations indexed

About

Hua Yan is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Hua Yan has authored 22 papers receiving a total of 251 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Hematology and 7 papers in Oncology. Recurrent topics in Hua Yan's work include Multiple Myeloma Research and Treatments (9 papers), Protein Degradation and Inhibitors (6 papers) and Phytochemical compounds biological activities (3 papers). Hua Yan is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Protein Degradation and Inhibitors (6 papers) and Phytochemical compounds biological activities (3 papers). Hua Yan collaborates with scholars based in China, Thailand and United States. Hua Yan's co-authors include Yingli Wu, Yang Cao, Jia Tong, Wenbin Xu, Yanhong Wang, Chongchong Wang, Nan Zhang, Shan Zhao, Wei Wei and Chunmin Ma and has published in prestigious journals such as Blood, PLoS ONE and Life Sciences.

In The Last Decade

Hua Yan

21 papers receiving 249 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hua Yan China 9 165 70 46 31 29 22 251
Xiaoming Zou United States 10 244 1.5× 68 1.0× 65 1.4× 21 0.7× 38 1.3× 12 345
Sen-Hao Xiao China 12 234 1.4× 47 0.7× 35 0.8× 21 0.7× 65 2.2× 14 298
Shanhe Yu China 13 235 1.4× 41 0.6× 63 1.4× 23 0.7× 56 1.9× 28 363
Farisa Syeda Canada 7 236 1.4× 36 0.5× 36 0.8× 15 0.5× 37 1.3× 9 377
Sarah Röthlisberger Colombia 7 235 1.4× 139 2.0× 31 0.7× 24 0.8× 81 2.8× 14 346
Hongyin Sun China 8 180 1.1× 32 0.5× 79 1.7× 24 0.8× 36 1.2× 12 304
Mai Itoh Japan 11 243 1.5× 58 0.8× 80 1.7× 9 0.3× 53 1.8× 31 361
Simin Qi China 7 308 1.9× 47 0.7× 155 3.4× 31 1.0× 34 1.2× 12 410
Savita Bhalla United States 9 211 1.3× 30 0.4× 109 2.4× 38 1.2× 37 1.3× 19 355
Lijun Wen China 9 210 1.3× 65 0.9× 19 0.4× 32 1.0× 70 2.4× 29 298

Countries citing papers authored by Hua Yan

Since Specialization
Citations

This map shows the geographic impact of Hua Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hua Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hua Yan more than expected).

Fields of papers citing papers by Hua Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hua Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hua Yan. The network helps show where Hua Yan may publish in the future.

Co-authorship network of co-authors of Hua Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Hua Yan. A scholar is included among the top collaborators of Hua Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hua Yan. Hua Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Wenbin, et al.. (2025). Targeting MTHFD2 alters metabolic homeostasis and synergizes with bortezomib to inhibit multiple myeloma. Cell Death Discovery. 11(1). 201–201. 3 indexed citations
2.
Liu, Jia, Zilu Zhang, Wenbin Xu, et al.. (2025). Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma. Blood Advances. 9(8). 1991–2005. 1 indexed citations
3.
Wang, Yanwei, Jingru Qiu, Hua Yan, et al.. (2024). The Bach1/HO-1 pathway regulates oxidative stress and contributes to ferroptosis in doxorubicin-induced cardiomyopathy in H9c2 cells and mice. Archives of Toxicology. 98(6). 1781–1794. 4 indexed citations
4.
Wang, Yizhi, Chenyu Guo, Lin Zhan, et al.. (2024). Fucoidan alleviates doxorubicin-induced cardiotoxicity by inhibiting ferroptosis via Nrf2/GPX4 pathway. International Journal of Biological Macromolecules. 276(Pt 1). 133792–133792. 16 indexed citations
5.
Liu, Jia, et al.. (2023). Integrative analysis of an endoplasmic reticulum stress‐related signature in multiple myeloma. The Journal of Gene Medicine. 26(1). e3595–e3595. 1 indexed citations
6.
7.
Cao, Yang, Meng Liu, Jia Liu, et al.. (2021). Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib. Cell Death and Disease. 12(4). 396–396. 16 indexed citations
8.
Zhang, Zilu, Jia Liu, Wenbin Xu, et al.. (2021). JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKKβ. Cancer Biology and Medicine. 19(5). 651–668. 5 indexed citations
9.
10.
11.
Tong, Jia, Qing Yu, Wenbin Xu, et al.. (2018). Montelukast enhances cytocidal effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway. Cancer Biology & Therapy. 20(3). 381–390. 8 indexed citations
12.
Wang, Yan, Nan Zhang, Wenbin Xu, et al.. (2017). MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death and Disease. 8(5). e2776–e2776. 49 indexed citations
13.
Liu, Yan, et al.. (2017). Clinical efficacy of radiotherapy combined with sodium glycididazole in the treatment of recurrent oesophageal carcinoma. Tropical Journal of Pharmaceutical Research. 15(12). 2719–2719.
14.
Yan, Hua, et al.. (2016). Short-term clinical effect of conformal radiotherapy combined with tegafur gimeracil oteracil potassiumin treating recurrent esophagus cancer. Pakistan Journal of Medical Sciences. 32(5). 1141–1145. 1 indexed citations
15.
Huang, Shang‐Yi, Yao Yu, W Y Kao, et al.. (2015). A Non-interventional Observational Registry of Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Lenalidomide (LEN) and Dexamethasone (DEX) in Taiwan. Clinical Lymphoma Myeloma & Leukemia. 15. e299–e299. 1 indexed citations
16.
Huang, He, Yang Cao, Wei Wei, et al.. (2013). Targeting Poly (ADP-Ribose) Polymerase Partially Contributes to Bufalin-Induced Cell Death in Multiple Myeloma Cells. PLoS ONE. 8(6). e66130–e66130. 19 indexed citations
17.
Yan, Hua, Yang Cao, Wei Wei, et al.. (2013). Oridonin Upregulates All-Trans Retinoic Acid Receptor Alpha and Induces Differentiation Of NB4 Cells Though NF-Kb Pathway. Blood. 122(21). 2909–2909. 1 indexed citations
18.
Zhao, Shan, Chunmin Ma, Chuanxu Liu, et al.. (2012). Autophagy inhibition enhances isobavachalcone-induced cell death in multiple myeloma cells. International Journal of Molecular Medicine. 30(4). 939–944. 40 indexed citations
19.
Yan, Hua, Zhixiang Shen, & Jianxiang Wang. (2008). A Multicentre, Randomized Study of FLAG Treatment in China(CHORT).. Blood. 112(11). 948–948. 1 indexed citations
20.
Gu, Bai-Wei, Jiong Hu, Lan Xu, et al.. (2001). Feasibility and clinical significance of real-time quantitative RT–PCR assay of PML-RARα fusion transcript in patients with acute promyelocytic leukemia. The Hematology Journal. 2(5). 330–340. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaoming Zou Breakdown of academic impact, for papers by Sen-Hao Xiao Breakdown of academic impact, for papers by Shanhe Yu Breakdown of academic impact, for papers by Farisa Syeda Breakdown of academic impact, for papers by Sarah Röthlisberger Breakdown of academic impact, for papers by Hongyin Sun Breakdown of academic impact, for papers by Mai Itoh Breakdown of academic impact, for papers by Simin Qi Breakdown of academic impact, for papers by Savita Bhalla Breakdown of academic impact, for papers by Lijun Wen
Rankless by CCL
2026